Qilu Pharmaceutical Co., Ltd.: Lung Neoplasms trials

The registry lists 12 Lung Neoplasms studies with Qilu Pharmaceutical Co., Ltd. as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06954246Phase 3
• a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.Not yet recruitingNCT06789796Phase 3
• Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFRNot yet recruitingNCT03381430Not applicable
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3
• Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT05801107Phase 2
• A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung CancerActive, not recruitingNCT05690945Phase 3
• A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05329025Phase 2
• Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05309629Phase 2
• A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Phase 2
• Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT04632758Phase 3
• To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung CancerStatus unknownNCT03195569
• Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerCompletedNCT03169335Phase 3